N-methyl-2-[3-((E)-2-pyridin-2-yl-vinyl)-1H-indazol-6-ylsulfanyl]-benzamide for the treatment of chronic myelogenous leukemia
The present invention relates to a method of treating chronic myelogenous leukemia in a subject comprising administering to the subject a compound, such as N-methyl-2-[3-((E)-2-pyridin-2-yl-vinyl)-1H-indazol-6-ylsulfanyl]-benzamide, that inhibits the T315I mutation in BCR-ABL tyrosine kinase, or a pharmaceutically acceptable salt thereof. The present invention also relates to a pharmaceutical composition comprising a compound such as N-methyl-2-[3-((E)-2-pyridin-2-yl-vinyl)-1H-indazol-6-ylsulfanyl]-benzamide, that inhibits the T315I mutation in BCR-ABL tyrosine kinase, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent.
1. A method of treating chronic myelogenous leukemia in a subject comprising administering to the subject a compound that inhibits the T315I mutation in BCR-ABL tyrosine kinase, wherein the compound is N-methyl-2-[3-((E)-2-pyridin-2-yl-vinyl)-1H-indazol-6-ylsulfanyl]-benzamide, or a pharmaceutically acceptable salt thereof.
2. The method of claim 1 , wherein the subject is human.
3. A method of treating chronic myelogenous leukemia in a subject having the T315I mutation in BCR-ABL tyrosine kinase, comprising administering to the subject a compound, which is N-methyl-2-[3-((E)-2-pyridin-2-yl-vinyl)-1H-indazol-6-ylsulfanyl]-benzamide, or a pharmaceutically acceptable salt thereof.
4. The method of claim 3 , wherein the subject is human.
5. A method of treating chronic myelogenous leukemia in a subject having the T315I mutation in BCR-ABL tyrosine kinase, comprising administering to the subject a compound that inhibits the T315I mutation in BCR-ABL tyrosine kinase, wherein the compound is N-methyl-2-[3-((E)-2-pyridin-2-yl-vinyl)-1H-indazol-6-ylsulfanyl]-benzamide, or a pharmaceutically acceptable salt thereof.
6. The method of claim 5 , wherein the subject is human.
7. A pharmaceutical composition for treating chronic myelogenous leukemia in a subject comprising a compound that inhibits the T315I mutation in BCR-ABL tyrosine kinase, wherein the compound is N-methyl-2-[3-((E)-2-pyridin-2-yl-vinyl)-1H-indazol-6-ylsulfanyl]-benzamide, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent.